Introduction
============

During the last decades, the incidence of malignant melanoma (hereafter called melanoma) has increased faster than any other solid tumor, and has developed from a very rare disease entity into a cancer with growing importance medically. Global incidence is about 160 000 new cases per year, with 48 000 deaths ([@ref1]). New Zealand and Australia have the highest incidence and mortality rates from melanoma in the world ([@ref2]). In USA ([@ref3]) and Europe ([@ref4], [@ref5]), incidence rates are similarly increasing. The contemporary incidence rate exceeding 125 cases per 100,000 men aged 65 and older in USA, making malignant melanoma the fifth most common cancer in older white men following prostate, lung, colorectal, and bladder cancer ([@ref6]). Solar radiation has been identified as a principal factor for the causation of melanoma ([@ref7]), other factors, such as obesity ([@ref8]), oral contraceptive ([@ref9]), decreased physical exercise ([@ref10]), smoking and alcohol ([@ref11]) might also contribute to the increasing incidence of malignancy.

Type 2 diabetes mellitus (T2DM) is serious and becoming increasingly common in many countries ([@ref12], [@ref13]), which accounts for 90-95% of all diagnosed cases of diabetes. Evidence-derived from case control studies, cohort studies, and meta-analyses, suggests that diabetes could increases the risks of site-specific cancers of breast ([@ref14]), kidney ([@ref15]), colorectal ([@ref16]), gastric ([@ref17]), liver ([@ref18]), endometrial ([@ref19]), thyroid ([@ref20]), lung ([@ref21]) and pancreatic ([@ref22]), but decreases the risk of prostate cancer ([@ref23]). Recently, a large population-based survey in USA indicated that the prevalence of melanoma in persons with diabetes was significantly higher than those without diabetes, and clinical studies demonstrated that melanoma was common among people with diabetes. Lifestyle risk factors for developing diabetes ([@ref24], [@ref25]), such as physical inactivity and obesity, have also been linked to an increased risk of melanoma ([@ref8], [@ref10]).

Thus, it has been hypothesized that diabetes itself may be a risk factor for melanoma. To present, epidemiology studies of the relationship between diabetes and melanoma have shown inconsistence results. To this end, we aimed to perform a meta-analysis of cohort studies to evaluate the association between T2DM and melanoma.

Methods
=======

Search strategy and selection criteria
--------------------------------------

Literature retrieval was conducted by searching Medline, PubMed, Embase and the Cochrane Library, up to February 2014 by two independent investigators (Qi Li and Qi Xiaoling). The search strategy included the following keywords: diabetes, diabetes mellitus, NIDDM, neoplasm(s), cancer, carcinoma, skin cancer and melanoma. The reference lists of pertinent articles were also inspected manually. We contacted the authors of included studies for additional eligible studies.

Inclusion and exclusion criteria
--------------------------------

Studies were eligible for the meta-analysis if they met the following inclusion criteria 1) a cohort design; 2) one of the exposure interests was T2DM; 3) one of the outcome of interests was melanoma; 4) rate ratio, hazard ratio or standardized incidence rates (SIR) with their 95% confidence intervals (CIs) (or data to calculate them) were reported. Studies were excluded if they 1) provided only an effect estimate with no means to calculate a CIs or 2) were derived from non-peer-reviewed sources or 3) only contained patients with type 1 diabetes or ([@ref4]) only provided standardized mortality rate without standardized incidence rate (because mortality rate could be confounded by survival related factors easily). When multiple publications on a same cohort were identified or when study populations overlapped, only the study of the most recent report or the publication with the most control for confounders was included, unless the reported outcomes were mutually exclusive.

Study selection and Data extraction
-----------------------------------

Data extracted from eligible studies included publication data (the first author's last name, year of publication, and country of population studied), year of the study conducted, case resource, methods of ascertainment of diabetes and outcome, the follow-up period, risk estimates with their corresponding confidence intervals, and variables adjusted for in the analysis. When studies provided more than one RRs according to the duration of diabetes before melanoma was diagnosed, we extracted and combined the RRs for individuals diagnosed with diabetes more than 1 year prior to the diagnosis of melanoma.

Quality evaluation
------------------

The Newcastle-Ottawa Scale (NOS) ([@ref26]) was applied to evaluate the qualities of the included studies. A 'star system' was used to judge data quality based on three broad perspectives for these studies: the selection, the comparability and the outcome or exposure of interest. The scores ranged from 0 to 9 scores. Studies with scores of 7 stars or greater were considered to be of high quality. The scores were added up to compare the study quality in a quantitative fashion. Two reviewers independently evaluated and crosschecked the quality of the included studies, as well as assessed the bias of the studies. Disagreements between the reviewers were resolved by open discussion.

Statistical analysis
--------------------

All statistical tests were performed using STATA, version 11.0 (STATA, College Station, TX, USA). We included in this meta-analysis reporting different measures of relative risks (RRs): rate ratio and standardized incidence rate (SIR). In practice, both of them yield similar estimates of RR because the absolute risk of melanoma is low.

The variance of the logRR from each study was calculated by converting the 95% CI to its natural logarithm by taking the width of the CI and dividing by 3.92. The pooled RR estimates with corresponding 95% CIs was derived with the method of DerSimonian and Laird ([@ref27], [@ref28]) using the assumptions of a random-effects model, which accounts for heterogeneity among studies (*I*^2^ ≥50%); otherwise, a fixed effects model was applied.

We conducted subgroup analyses stratified by different participants and study characteristics. Only the studies based on rate ratio or SIR were included for subgroup analysis. To assess heterogeneity among studies, we used the Cochran Q and *I*^2^ statistics. This was used to test whether the differences obtained between studies was due to chance. For the Q statistic, a *P* value \< 0.10 was considered statistically significant for heterogeneity; for *I*^2^, a value \>50% was considered as a measure of severe heterogeneity. Publication bias was evaluated using the funnel plot and Begg's and Egger's test, a *P* value of less than 0.10 was considered to be statistically significant.

Results
=======

Description of the eligible studies
-----------------------------------

The publication search process is shown in [Fig. 1](#F1){ref-type="fig"}. First, a total of 2052 potentially relevant publications up to February 2014 were systematically identified through the previously listed databases. Of them, 1727 articles were excluded because they either did not meet the inclusion criteria or failed to provide adequate information to determine whether the criteria were satisfied in the first round screening after reading titles or abstracts. Among the remaining 325 studies, 306 articles were excluded because they did not contain data about melanoma or skin cancer. The remaining 19 articles were subjected to full-text reviews. And then, 11 articles were excluded because they were case reports, cross-sectional survey, case-control study, or only provided relationship of type 1 diabetes and melanoma, other type of skin cancer, or SMR of diabetes and melanoma. Finally, 9 cohort studies from 8 literatures ([@ref29]-[@ref36]) were eligible and included in the meta-analysis.

![Flow chart of the literature search strategy to identify cohort studies on melanoma and T2DM](IJPH-43-857-g001){#F1}

We established a database according to the information extracted from each study. Detailed characteristics of the 9 studies are listed in [Table 1](#T1){ref-type="table"}. The countries in which the studies were conducted were as follows: USA (n = 3); Sweden (n = 3); UK (n=2); Denmark (n=1). All the cohorts included in this Meta-analysis included both men and women, expect one cohort consisted entirely of men veterans.

A total of 1,071,257 persons (range: 7,771-594,815) were included in the 9 cohort studies, with 1,876 cases of melanoma were reported. Among the 9 studies, potential confounders were controlled in 6 studies (at least for age), 5 of them adjusted by gender, 2 of them adjusted by obesity, 3 of them were population-based cohort, whereas the other 6 were hospital-based cohorts. Quality assessment of studies was performed using the NOS method. The results ranged from a star rating of 5 to 9 (with a mean star rating of 7), with a higher value indicating the better methodology ([Table 2](#T2){ref-type="table"}).

![Analysis of studies were examined the association between T2DM and melanoma. RRs and 95% CI for all studies and the overall effect estimate are reported in the log scale. Among diabetics, the overall RR for melanoma is statistically significant at 1.15 (95% CI, 1.00-1.32)](IJPH-43-857-g002){#F2}

Diabetes and melanoma risk
--------------------------

As shown in [Fig. 2](#F2){ref-type="fig"}, the summary RR with 95% CI was 1.15 (95% CI, 1.00-1.32) in a random-effects model for individuals with T2DM compared with those without T2DM (Q =18.85, *P*=0.016, *I*^2^ =57.6%).

We then conducted subgroup meta-analyses on the basis of case source and geographical area ([Table 3](#T3){ref-type="table"}). The association between T2DM and melanoma was somewhat stronger in population-based studies (pooled RR 1.82, 95% CI, 1.31-2.62; test for heterogeneity Q =2.38, *P* = 0.303,

*I*^2^ =16.1%) than in hospital-based studies (pooled RR 1.10, 95% CI, 1.03-1.17; test for heterogeneity Q =4.71, *P*= 0.452, *I*^2^ =0%). Subgroup analysis based on geographical area revealed that the pooled RR was statistically significant in USA (pooled RR =1.47; 95 % CI=1.00-2.17; test for heterogeneity Q =8.31, *P* =0.016, *I*^2^ =58.1%), but no significant positive association was found in Sweden, UK and Denmark.

###### 

Characteristics of 9 cohort studies of T2DM and melanoma based on rate ratio and standardized incidence rate

  Year             First author             Country   Study population                            Diagnosis of DM           Study period   Age range (yr)                      Mean follow-up(year)   Gender   SIR/RR(95%CI)        Adjustment factors
  ---------------- ------------------------ --------- ------------------------------------------- ------------------------- -------------- ----------------------------------- ---------------------- -------- -------------------- ------------------------------------------------------------------------------
  2010([@ref31])   Kari Hemminki            Sweden    National wide hospital discharge database   Hospital disease record   1964-2007      39\--                               15                     Both     1.03 (0.88-1.20)\*   Age, sex, period, socioeconomic status, obesity and region
  2007([@ref33])   Par Stattin              Sweden    Northern Sweden health and disease cohort   Fasting glucose level     1985-2013      29-61                               8.25                   Both     2.16(1.14-4.35)      Age, calendar year and smoking
  2011([@ref30])   Elizabeth A.Atchison     USA       U.S. veterans men                           Hospital disease record   1969-1996      18-100                              10.5                   Male     1.13(1.03-1.24)      Age, time, latency, race, obesity and number of visits
  2011([@ref29])   C.J.Wotton               UK        Hospital admissions and deaths data         Hospital disease record   1963-1998      ≥ 30                                NA                     Both     1.15(0.68-1.82)      sex, age in 5-year bands, time period in single calendar years and districts
  2011([@ref29])   C.J.Wotton               UK        Hospital admissions and deaths data         Hospital disease record   1999-2008      ≥ 30                                NA                     Both     0.93(0.42-1.79)      sex, age in 5-year bands, time period in single calendar years and districts
  2009([@ref32])   Marianne Ulcickas Yood   USA       National population-based database          Hospital disease record   2000-2004      18-                                 3.6                    Both     1.63(1.21-2.19)      Age, gender
  1997([@ref34])   Wideroff                 Denmark   Hospital discharge database                 Hospital disease record   1977-1989      mean(male) : 64 ; mean(female):69   5.7                    Both     1.0(0.84-1.20)       NA
  1991([@ref35])   Hans-Olov Adami          Sweden    Hospital inpatient register database        Hospital disease record   1965-1984      20-                                 5.2                    Both     0.92(0.71-1.34)      NA
  1982([@ref36])   Mark Ragozzino           USA       Hospital medical reports                    Hospital medical report   1945-1969      NA                                  8.7                    Both     4.3(0.9-12.5)        NA

\*Refer to standardized incidence rate (SIR)

###### 

Quality indicators from Newcastle-Ottawa scale

  *Study*          *Selection*   *Comparability*   *Exposure/Outcome*   Score                                 
  ---------------- ------------- ----------------- -------------------- ------- ----- ----- ----- ----- ----- ---
  Hemminki 2010    yes           yes               yes                  yes     yes   Yes   Yes   Yes   yes   9
  Stattin 2007     yes           yes               yes                  yes     yes   yes   no    yes   yes   8
  Atchison 2011    yes           yes               yes                  yes     yes   yes   yes   yes   yes   9
  Wotton 2011(a)   yes           yes               yes                  yes     yes   no    yes   yes   no    7
  Wotton 2011(b)   yes           yes               yes                  yes     yes   no    yes   yes   yes   8
  Yood 2009        yes           yes               yes                  yes     yes   no    yes   no    yes   7
  Wideroff 1997    yes           no                yes                  yes     no    no    yes   yes   no    5
  Adami 1991       yes           no                yes                  yes     no    no    yes   yes   yes   6
  Ragozzino 1980   yes           no                yes                  yes     no    no    yes   yes   yes   6

Footnote:

1, indicates exposed cohort truly representative; 2, the non exposed cohort drawn from the same community; 3, ascertainment of exposure by secure record or structured interview; 4, outcome of interest was not present at start of study; 5A, cohorts comparable on basis of sex and age; 5B, cohorts comparable on other factor(s); 6, quality of outcome assessment; 7, follow-up long enough for outcomes to occur; and 8, complete follow up

###### 

Stratified analysis of relative risks for the association between T2DM and melanoma

  Subgroup                   Reference                             *P* value for overall effect   Pooled RR (95% CI)   Tests for heterogeneity           
  -------------------------- ------------------------------------- ------------------------------ -------------------- ------------------------- ------- ------
  Adjustment for age                                                                                                                                     
  Yes                        [@ref29]-[@ref33]                     0.019                          1.21(1.03-1.42)      10.98                     0.052   54.5
  No                         [@ref34]-[@ref36]                     0.753                          1.06(0.75-1.49)      4.99                      0.083   59.9
  Adjustment for gender                                                                                                                                  
  Yes                        [@ref29]-[@ref32]                     0.031                          1.17(1.01-1.35)      7.62                      0.107   47.5
  No                         [@ref33]-[@ref36]                     0.253                          1.25(0.85-1.85)      9.81                      0.02    69.4
  Adjustment for obesity                                                                                                                                 
  Yes                        [@ref30],[@ref31]                     0.058                          1.11(1.00-1.24)      1.73                      0.189   42.2
  No                         [@ref29],[@ref32]-[@ref36]            0.100                          1.25(0.96-1.64)      18.11                     0.009   64.9
  Diabetes cohort resource                                                                                                                               
  Population-based           [@ref32],[@ref33],[@ref36]            0                              1.85(1.31-2.62)      2.38                      0.303   16.1
  Hospital-based             [@ref29]-[@ref31],[@ref34],[@ref35]   0.006                          1.10(1.03-1.17)      4.71                      0.452   0
  Country                                                                                                                                                
  USA                        [@ref30],[@ref32],[@ref36]            0.053                          1.47(1.00-2.17)      8.31                      0.016   58.1
  Sweden                     [@ref31],[@ref33],[@ref34]            0.455                          1.08(0.88-1.34)      4.78                      0.092   75.9
  UK                         [@ref29]                              0.726                          1.08(0.72-1.62)      0.23                      0.635   0
  Study quality                                                                                                                                          
  7 stars or greater         [@ref29]-[@ref33]                     0.019                          1.21(1.03-1.42)      10.98                     0.052   54.9
  Below 7 stars              [@ref34]-[@ref36]                     0.753                          1.06(0.75-1.49)      4.99                      0.083   59.9

The impact of confounding factors such as age, gender and obesity on the assessment of the relative risks between T2DM and melanoma were further investigated. Five studies provided data on melanoma risk adjusted for age. In a stratified analysis, diabetes were at an increased risk of developing melanoma in the studies adjusted for age (pooled RR =1.21, 95% CI=1.03-1.42; test for heterogeneity Q =10.98, *P* =0.052, *I*^2^ =54.5%), but the overall slope-association of studies without adjusted by age was null, the pooled RR was 1.06(95%CI, 0.75-1.49).

Similarly, when we restricted the meta-analysis to studies adjusted for gender, we found a positive association between T2DM and melanoma, the pooled RR was 1.17(95%CI, 1.01-1.35; test for heterogeneity Q =7.62, *P* =0.107, *I*^2^ =47.5%), but the overall slope-association of studies without adjusted by gender was null, the pooled RR was 1.24(95%CI, 0.85-1.85).

When we restricted the meta-analysis to the studies adjusted for obesity, the positive association between T2DM and melanoma risk remained, the pooled RR was 1.11(95%CI, 1.00--1.24; test for heterogeneity Q =1.73, *P* =0.189, *I*^2^ =42.2%).

![Funnel plot of log RR of developing melanoma, according to the SEs of all studies in analysis. Y-axis, RRs on the logarithmic scale; X-axis, SE. The horizontal line is drawn at the pooled log RR. Begg-Mazumdar test (*P* = 0.404) and Egger test (*P* = 0.392)](IJPH-43-857-g003){#F3}

In addition, the summary estimate from studies whose quality was considered high (with a start rating of 7 stars or greater by assessment using NOS method) was significantly higher than from others: 1.21 (95% CI 1.03--1.42) vs. 1.06(0.75-1.49). In the study consisted of entirely veteran men, men with diabetes had a higher risk of melanoma than those without diabetes, with a RR and 95% CI of 1.13(1.03--1.24).

Publication bias of the studies
-------------------------------

There was no funnel plot asymmetry for the association between diabetes and melanoma risk ([Fig.3](#F3){ref-type="fig"}). *P* values for Begg's adjusted rank correlation test and Egger's regression asymmetry test were 0.404 and 0.392, respectively, indicating a low probability of publication bias.

Discussion
==========

Findings from this meta-analysis indicate that individuals with T2DM may slightly increase relative risk of developing melanoma compared with non-T2DM individuals. T2DM and melanoma share some similar risk factors, such as aging and obesity ([@ref8]). Thus, the observed increased risk of melanoma associated with a history of diabetes may reflect confounding by these risk factors. However, a statistically significant association was still found when the analysis was limited to studies that adjusted for age and obesity, the pooled RR and 95% CI were 1.21(1.03 to 1.42) and 1.11(1.00 to 1.24), respectively. These results indicated that diabetes might be an independent risk factor of melanoma.

Several mechanisms have been proposed to explain the biological plausibility of T2DM increasing the risk of melanoma. First, T2DM is usually associated with insulin resistance for long periods both before and after disease onset ([@ref37]), which has indeed recently been acknowledged as an independent risk factor for melanoma ([@ref38]). Insulin resistance and secondary chronic hyperinsulinemia may stimulate tumor growth by increasing bioavailable Insulin-like Growth Factors- I (IGF-I), well-known to promote tumor cell proliferation and metastases ([@ref39]) in T2DM. Second, recently, studies suggest that vitamin D deficiency correlates with diabetes ([@ref40]), and polymorphisms in the vitamin D receptor (VDR) gene are implicated in susceptibility to diabetes ([@ref41]), interestingly, those genes such as FokI, BsmI, and TaqI had also been reported to be affecting the risk of developing melanoma ([@ref42]-[@ref45]). Besides, other mechanisms like leptin and serum adiponectin were both regarded as risk factors of diabetes ([@ref46]) and the development of melanoma ([@ref47], [@ref48]).

To some extent, some limitations may affect the objectivity of the conclusions and should be considered when interpreting the results. Firstly, the cohorts of diabetes in several studies were hospital-based, the comparison group (i.e. the general population) includes individuals with diabetes, this would tend to attenuate any true association between T2DM and melanoma risk. Our results have shown that the association between T2DM and melanoma was stronger in population-based studies than in hospital-based studies. Secondly, the baseline information of several studies was so meager that we cannot recognize the comparability between the cohort and the controls. Unadjusted effect estimates have been published in 3 studies of lower quality, and the overall slope-association of these studies was null 1.06(0.75-1.49). Thirdly, as in all meta-analysis, the possibility of publication bias is of concern. However, a formal statistical test did not provide evidence for such bias. Finally, most of the studies met our inclusion criteria conducted in European and North American, which might influence the generalizability of the findings to other types of geographic areas.

Conclusion
==========

Despite the limitations, this meta-analysis supports the hypothesis that T2DM might be an independent risk factor for melanoma. It should be noted that this meta-analysis may have important health implication. T2DM is a serious and rapidly growing health problem, thus it is important to note that the increased severity and prevalence of T2DM could contribute significantly to the incidence of melanoma, even if the effect is small. Hence, it is urgent to implement effective intervention strategies for T2DM in context of efforts for enhanced melanoma prevention and control. Clinician caring for patients with T2DM should remain alert to melanoma and minimize the number of missed opportunities for its treatment.

Further large-scale prospective studies are needed to test specifically the effect of T2DM on melanoma risk, and fully elucidate the underlying pathophysiologic mechanisms.
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